The U.S. Food and Drug Administration on Thursday formalised an expanded prescribing indication for Merck's Gardasil 9 (human papillomavirus 9-valent vaccine), updating labelling guidance to more explicitly support shared clinical decision-making for adults aged 27 through 45 who remain unvaccinated or incompletely vaccinated against HPV-related cancers, including cervical, oropharyngeal, and anal cancers. The move builds on a standing 2018 approval but adds new post-market surveillance data that Merck submitted to the agency earlier this year, according to regulatory documents published Thursday morning.

The timing is significant. Multiple national health systems — including programmes in South Korea, Australia, and several Canadian provinces — are simultaneously running accelerated HPV immunisation campaigns through May 31, with eligibility windows designed to catch women who missed adolescent vaccination. The FDA's updated guidance is expected to reinforce messaging from the American Cancer Society and CDC that adults in the 27–45 bracket should discuss catch-up vaccination with their physicians rather than assuming they are too old to benefit.

Merck executives noted in a brief statement that the updated label clarifies clinical communication pathways for primary care physicians and gynaecologists, a group that surveys have shown remains uncertain about counselling older patients on HPV vaccination. The company said it does not anticipate supply constraints, pointing to expanded manufacturing capacity at its Durham, North Carolina facility that came online in late 2025.

Public health advocates welcomed the development, arguing it arrives at a moment of renewed awareness around cervical cancer. Prominent cancer survivors speaking publicly about their diagnoses in recent weeks — including figures in South Asia who have highlighted late-stage detection — have generated broader media attention around preventable HPV-linked malignancies. The National Cervical Cancer Coalition said it would update its patient-facing materials within 48 hours to incorporate the clearer FDA language.

Analysts at SVB Securities estimated that the label clarification could modestly lift Gardasil 9 U.S. revenues by approximately 4–6 percent over the next twelve months as more insurers formalise coverage pathways for the 27–45 cohort. Merck shares were marginally higher in pre-market trading. The CDC's Advisory Committee on Immunization Practices is not expected to convene an emergency session but is scheduled to revisit HPV vaccination guidance at its June meeting in Atlanta.